Pfizer and biontech receive chmp positive opinion for covid-19 vaccine booster in the european union

New york and mainz, germany, october 4 , 2021— pfizer inc. (nyse: pfe, “pfizer”) and biontech se (nasdaq: bntx, “biontech”) today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) issued a positive opinion on the administration of the companies' covid-19 vaccine as a booster dose at least six months after the second dose in individuals 18 years of age and older. the european commission (ec) will review the chmp recommendation and is expected to make a final decision on a variation to the conditional marketing authorization in the near future. if the ec grants the variation regarding a booster dose, the decision will be immediately applicable to all 27 eu member states.
BNTX Ratings Summary
BNTX Quant Ranking